Pulmonary function tests (PFTs) are indispensable tools in diagnosing and managing respiratory diseases. However, their interpretation can be complex, necessitating a comprehensive understanding of the test parameters and their clinical implications.
The primary parameters include Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and the FEV1/FVC ratio. FVC reflects the maximum amount of air a patient can exhale forcefully after a full inhalation. FEV1 measures the volume exhaled in the first second of this maneuver. The FEV1/FVC ratio helps differentiate obstructive from restrictive lung diseases.
Interpretation involves comparing the patient's values with predicted normal values, adjusted for age, sex, height, and ethnicity. In obstructive diseases such as asthma or COPD, FEV1 and the FEV1/FVC ratio are reduced, while FVC may be normal or decreased. In restrictive diseases like pulmonary fibrosis, all values are typically reduced, but the FEV1/FVC ratio remains normal or increased.
Assessing bronchodilator responsiveness is crucial in differentiating asthma from COPD. An increase in FEV1 or FVC by at least 12% and 200ml post-bronchodilator indicates significant reversibility, suggestive of asthma.
The Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) is another vital parameter. Reduced DLCO suggests impaired gas exchange and is seen in interstitial lung diseases and emphysema. However, it can also be decreased in anemia and pulmonary hypertension, underlining the importance of comprehensive clinical correlation.
Interpreting PFTs is a nuanced process requiring an understanding of the underlying physiology, test parameters, and their interrelationships. This knowledge, combined with a thorough clinical assessment, ensures accurate diagnosis and effective patient management in respiratory medicine.
1.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
2.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
3.
New imaging guidelines for head and neck cancers, a step toward practice change
4.
How wildfires pose challenges to cancer care
5.
Annual whole-body, low-dose CT aids management of smoldering multiple myeloma
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy
3.
Geriatric Medicine Through Long-Term Functional Survivorship After Cancer in Older Adults
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Advanced Directions in Oncology and Quality Improvement
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
When Unexplained Bruising May Require Blood Testing
2.
Current Scenario of Cancer- The Incidence of Cancer in Men
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation